Savavet Galibor (Ursodeoxycholic Acid IP 125 mg / 5 ml) Oral Suspension for Dogs & Cats

Active Formulation Matrix & Pharmacological Profile

ParameterSpecificationPharmacological Mechanism & Clinical RoleActive Pharmaceutical IngredientUrsodeoxycholic Acid (UDCA / Ursodiol) IPNaturally occurring dihydroxy tertiary hydrophilic bile acid.Concentration Strength125 mg per 5 ml (25 mg / ml)Calibrated liquid concentration for accurate feline and canine weight-based dosing.Primary Therapeutic ActionsCholeretic, Cytoprotective, Antiapoptotic, ImmunomodulatoryIncreases bile secretion, protects hepatocytes, prevents programmed cell death, and modulates immune responses.Absorption & BioavailabilityHigh when administered with foodReadily absorbed from the small intestine via passive non-ionic diffusion; enhanced by dietary lipids.Hepatic Extraction & SecretionHigh First-Pass Clearance (~70% to 90%)Extensively cleared by the liver and conjugated with taurine/glycine, then excreted into the biliary canaliculi.Vehicle BaseFlavored Sorbitol Suspension BasePromotes voluntary acceptance and uniform active suspension.

Clinical Veterinary Indications

• Canine Chronic Hepatitis: Long-term supportive medical therapy to slow fibrotic progression and lower elevated serum liver enzymes (ALT, ALP, Total Bilirubin).

• Feline Cholangitis & Cholangiohepatitis Complex (CCH): Management of suppurative or lymphocytic biliary tract inflammation in cats (frequently associated with feline triaditis: concurrent IBD, pancreatitis, and cholangitis).

• Intrahepatic Cholestasis: Relief of impaired bile flow without physical mechanical obstruction.

• Biliary Sludge & Non-Obstructive Gallbladder Mucoceles: Early-stage dissolution of thick, inspissated biliary mucus and cholesterol gravel.

• Hepatic Lipidosis (Fatty Liver Syndrome): Supportive recovery therapy in recovering anorexic cats to clear secondary intrahepatic cholestasis.

• Toxic or Drug-Induced Hepatopathy: Cytoprotective shielding during liver recovery following hepatotoxin exposure or long-term medication use.

Comparison: Savavet Galibor (UDCA) vs. SAMe / Silybin (e.g., Lisybin) vs. Liv.52

Clinical ParameterSavavet Galibor (Ursodiol) [Current]SAMe + Silybin Complex (Lisybin)Herbal Liver Tonics (Liv.52)Primary Mode of ActionCholeretic (Drives bile flow) & replaces toxic bile acidsAntioxidant (Glutathione precursor) & membrane repairGeneral botanical digestive supportAction on Bile Sludge & StonesDirect chemical dissolution & flushingIndirect antioxidant supportMinimalRole in Cholestasis / JaundiceFirst-line prescription interventionSupportive hepatoprotectiveMild supportiveTarget Organ FocusBiliary canaliculi, gallbladder & liver cellsIntracellular hepatocyte metabolismGeneral hepatic metabolismAdministration with FoodAdminister with meals (Maximizes absorption)Strictly on an empty stomach (Fasted)Administer with foodIdeal Clinical SynergyFrequently combined with SAMe/Silybin for dual bile-flow and intracellular antioxidant coverage.

Dosage & Administration Protocol

Strictly for oral administration in dogs and cats under direct veterinary direction:

Standard Clinical Veterinary Dosing Regimens:

• General Dose Rate (Dogs & Cats): 10 mg to 15 mg Ursodeoxycholic Acid per kg body weight daily (administered either as a single daily dose or divided into two equal doses of 5 to 7.5 mg/kg every 12 hours).

• Equivalent Suspension Volume (25 mg/ml):

  • Dogs: Approximately 0.4 ml to 0.6 ml per kg body weight daily (or 2 ml to 3 ml per 5 kg body weight daily).

  • Cats: Approximately 0.2 ml to 0.3 ml per kg body weight daily (typically 0.8 ml to 1.5 ml total daily volume for an adult cat).

Weight-Based Daily Dosing Reference (at ~10–12.5 mg/kg/day):

Pet Type & Body WeightDaily UDCA DoseGalibor Suspension Daily Volume (25 mg/ml)Practical ScheduleCat (3.0 kg to 4.0 kg)30 mg to 40 mg1.2 ml to 1.6 mlDivide into 0.6–0.8 ml twice daily with mealsSmall Dog (5.0 kg)50 mg to 60 mg2.0 ml to 2.4 mlGive with morning and evening foodMedium Dog (10.0 kg)100 mg to 125 mg4.0 ml to 5.0 ml2.0 ml to 2.5 ml twice dailyLarge Dog (20.0 kg)200 mg to 250 mg8.0 ml to 10.0 ml4.0 ml to 5.0 ml twice dailyLarge Dog (30.0 kg)300 mg to 375 mg12.0 ml to 15.0 ml6.0 ml to 7.5 ml twice daily

Administration Guidelines:

1. Shake Well (Crucial): Shake the bottle thoroughly before each use to ensure the active microsuspension is evenly dispersed.

2. Administer With Food: Always give Galibor with or immediately after a meal. Dietary fats stimulate gall bladder contraction and bile acid circulation, enhancing the absorption and physiological integration of UDCA.

3. Syringe Delivery: Use a calibrated oral dosing syringe to measure the liquid accurately. Dispense slowly into the side of the pet's mouth between the cheek and teeth, allowing natural swallowing.

4. Treatment Duration: Chronic hepatobiliary conditions often require multi-month therapy (frequently 2 to 6 months or continuous maintenance), monitored via periodic liver panel blood tests (ALT, ALP, Bilirubin).

Product Specifications

ParameterDetailsBrandSavavet (Sava Healthcare Limited)ManufacturerFinecure Pharmaceuticals Ltd.Product Trade NameGalibor Oral SuspensionActive Pharmaceutical IngredientUrsodeoxycholic Acid (UDCA) IP 125 mg per 5 ml (25 mg/ml)Pharmacological ClassCholeretic, Cytoprotective & Hepatoprotective AgentDosage FormFlavored Oral Liquid SuspensionNet Volume100 ml Dispensing Bottle with Measuring Cap/SyringeTarget SpeciesDogs and CatsPrescription StatusPrescription Veterinary Medicine (Rx Required)

Contraindications, Safety Warnings & Drug Interactions

• ABSOLUTE CONTRAINDICATION (Complete Biliary Obstruction): Never administer Galibor to patients with complete mechanical obstruction of the extrahepatic biliary tract (such as obstructive choledocholithiasis, complete biliary duct stricture, or pancreatitis-induced total ductal occlusion). Because UDCA stimulates fluid bile production, driving bile against a complete obstruction risks gallbladder rupture and fatal bile peritonitis.

• Drug Interactions (Antacids & Binding Resins): Do not co-administer simultaneously with aluminum-based antacids or bile acid sequestering resins (such as Cholestyramine). These agents physically bind UDCA in the gut lumen, preventing absorption. Separate administration by at least 2 hours.

• Mild Digestive Signs: Transient gastrointestinal signs, such as mild loose stools or occasional vomiting, may occur in sensitive pets. These generally resolve when the medication is administered alongside meals.

• Storage Instructions: Store at room temperature (below 30°C) in a dry place away from direct heat and sunlight. Do not freeze. Keep the bottle tightly capped and out of reach of children and domestic pets.